Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00612638 · ClinicalTrials.gov registry record · Phase 1
Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT00612638 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 96 participants.
The verdict
NCT00612638, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
Objectives: To determine maximum tolerated dose of CPT-11 when administered following Temodar plus O6-benzylguanine To characterize any toxicity associated w combo of CPT-11 + Temodar plus O6-BG To observe pts for clinical antitumor response when treated w combo of CPT-11 + Temodar + O6-BG
Interventions
- DRUG Temodar, O6-BG, and Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2005-01 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00612638
The ClinicalTrials.gov registry entry for NCT00612638 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Temodar, O6-BG, and Irinotecan is the first listed.
NCT00612638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00612638 about?
NCT00612638 is a clinical study titled "Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas". Objectives: To determine maximum tolerated dose of CPT-11 when administered following Temodar plus O6-benzylguanine To characterize any toxicity associated w combo of CPT-11 + Temodar plus O6-BG To observe pts for clinical antitumor response when treated w combo of CPT-11 + Temodar + O6-BG
What is the current status of trial NCT00612638?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2005-01. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00612638?
The interventions under investigation include: Temodar, O6-BG, and Irinotecan (DRUG).
Who is sponsoring clinical trial NCT00612638?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.